0001437749-24-008585.txt : 20240320 0001437749-24-008585.hdr.sgml : 20240320 20240320073015 ACCESSION NUMBER: 0001437749-24-008585 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240320 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474671997 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 24766287 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 8-K 1 mbrx20240318c_8k.htm FORM 8-K mbrx20240318c_8k.htm
false 0001659617 0001659617 2024-03-20 2024-03-20
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 20, 2024
 
mbrx20240318c_8kimg001.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification
No.)
 
5300 Memorial Drive, Suite 950, Houston, TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed from last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
 
 
 
Item 7.01
Regulation FD Disclosure.
 
On March 20, 2024, Moleculin Biotech, Inc. (the “Company”), issued a press release that it will report its financial results for the year ended December 31, 2023, on Friday, March 22, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday, March 25, 2024 at 8:30 AM ET.
 
A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
Exhibit
No.
Description
 
99.1
 
104
Cover page Interactive Data File (formatted as Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC. 
  
       
       
 
Date:
 March 20, 2024
  
       
 
By:
 /s/ Jonathan P. Foster
  
   
 Jonathan P. Foster
  
 
 
 EX-99.1 2 ex_641515.htm EXHIBIT 99.1 ex_641515.htm

Exhibit 99.1

 logo.jpg

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

 

In-depth discussion of stratification of Company’s 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML)

 

Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study

 

HOUSTON, March 20, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2023, on Friday afternoon, March 22, 2024. Moleculin management will host a conference call and live webcast to discuss clinical, operational and financial results on Monday morning, March 25, 2024 at 8:30 AM ET.

 

Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.

 

About Moleculin Biotech, Inc.

 

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

 

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. 

 

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

 

Investor Contact:

 

JTC Team, LLC

Jenene Thomas

(833) 475-8247

MBRX@jtcir.com

 

 
 EX-101.SCH 3 mbrx-20240320.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 mbrx-20240320_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 mbrx-20240320_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 mbrx-20240320_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo.jpg begin 644 logo.jpg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end GRAPHIC 8 mbrx20240318c_8kimg001.jpg begin 644 mbrx20240318c_8kimg001.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information
Mar. 20, 2024
Document Information [Line Items]  
Entity, Registrant Name MOLECULIN BIOTECH, INC.
Document, Type 8-K
Document, Period End Date Mar. 20, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37758
Entity, Tax Identification Number 47-4671997
Entity, Address, Address Line One 5300 Memorial Drive, Suite 950
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77007
City Area Code 713
Local Phone Number 300-5160
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Title of 12(b) Security Common Stock
Trading Symbol MBRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0001659617
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,8[=%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #&.W18RKGC?.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VG%0^CVLN))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS M#4RG@]0^XG/T 2-93#>S&\8D==BP(U&0 $D?T:E4Y\28FWL?G:+\C <(2G^H M T+#^1TX)&44*5B 55B)K.^,ECJB(A_/>*-7?/B,0X$9#3B@PY$2B%H ZY>) MX30/'5P!"XPPNO1=0+,22_5/;.D .R?G9-?4-$WUU)9&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MQCMT6)/R/1Y.! I! !@ !X;"]W;W)K$]/=2/6F5XP9\I$F0O>6TWI5PX_6Y^;:+Z79F9A LV441G:4K5]I8E ML[ O[D-FG9 MWN,/SC;ZJ$WLJ\RE?+,GX[CG>):()2PR5H+"X9T-69)8)>#X=R_J%,^T X_; M!_7[_.7A9>94LZ%,OO/8K'K.M4-BMJ!98E[EYH'M7ZAE]2*9Z/P_V>SZ-EL. MB3)M9+H?# 0I%[LC_=A/Q-& AG]B0+ ?$.3HV4;^ MJOEH@./"KLK4*+C+89SIW\DH@TDV9"!B,A*&FRT9B]UJPZQU70,/L5W=:"]X MNQ,,3@@^475% N\"_H+F_X>[P%8 !@5@D.LUZ@"/J,C?C]"+C U+]3]5B#O) M9K6D#?0;O:81ZSD0R9JI=^;T/_WBM[W?$>!& =S U/N[2;P@KVS)M5$4T)]I MRJHP<:&GE\?1\-OC^)G>6"H5IPFY4U!@($@R#D'2:7D(L^^5_NS]'/706C2$X$QN MJNT9UWN0MJ@(C.VH=O@_QU;DQT3)=RZBRBFM$9W]B;&59<-'3?Y'MHG4!A;I M+[X^F;4UDF'H>5@@^F6)\'%KS]=P %]1IU%P@=!O8"!E(?!Q)W^4$(;YOKE3RX2BU/:?P^;MH3Q2XCF!X&"99_&LV8B)DB+XO%B?7# M]6K)R@K@XW[] ]E8ZPS(:@%QV5K L@3XY]6 4!].[P5>, MJ73S #?C 81ZG(?[?4*7E2RX0&T,E7X>X%9\B.\AT"AP]C'DW0?YPJJC"-?R MX..PW>JT_W^'3[!(:$T2=@"U+RK$-Q9[;;$NQ,CU_DV="X-;&KS MYHI1L 7; >XOI#2'$[NS+7Z8Z/\'4$L#!!0 ( ,8[=%B?H!OPL0( .(, M - >&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( ,8[ M=%B7BKL

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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mbrx.com/20240320/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mbrx-20240320.xsd mbrx-20240320_def.xml mbrx-20240320_lab.xml mbrx-20240320_pre.xml mbrx20240318c_8k.htm mbrx20240318c_8kimg001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mbrx20240318c_8k.htm": { "nsprefix": "mbrx", "nsuri": "http://www.mbrx.com/20240320", "dts": { "schema": { "local": [ "mbrx-20240320.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "mbrx-20240320_def.xml" ] }, "labelLink": { "local": [ "mbrx-20240320_lab.xml" ] }, "presentationLink": { "local": [ "mbrx-20240320_pre.xml" ] }, "inline": { "local": [ "mbrx20240318c_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.mbrx.com/20240320/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mbrx20240318c_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mbrx20240318c_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.mbrx.com/20240320/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001437749-24-008585-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-008585-xbrl.zip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mbrx20240318c_8k_htm.xml IDEA: XBRL DOCUMENT 0001659617 2024-03-20 2024-03-20 false 0001659617 8-K 2024-03-20 MOLECULIN BIOTECH, INC. DE 001-37758 47-4671997 5300 Memorial Drive, Suite 950 Houston TX 77007 713 300-5160 false false false false false Common Stock MBRX NASDAQ